BMY Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Stats
Today's Volume	42.29M
Average Volume	15.46M
Market Cap	90.60B
EPS	$0 ( 2024-02-02 )
Last Dividend	$0.600 ( 2024-01-04 )
Next Dividend	$0 ( N/A )
P/E	11.58
ATR14	$0.0500 (0.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Shanahan Karin	Sell	3 306	Restricted Stock Units
2024-04-01	Shanahan Karin	Buy	3 306	Common Stock, $0.10 par value
2024-04-01	Shanahan Karin	Sell	1 196	Common Stock, $0.10 par value
2024-03-31	Yale Phyllis R	Buy	645	Deferred Share Units
2024-03-31	Storch Gerald L	Buy	691	Deferred Share Units

INSIDER POWER
31.44
Last 100 transactions
Buy: 432 337 \| Sell: 225 479

Volume Correlation

Long: 0.09 (neutral)

Short: -0.85 (strong negative)

Signal:(44.957) Neutral

Bristol-Myers Squibb Co Correlation

10 Most Positive Correlations
UVV	0.926
AJAX	0.919
PYN	0.908
BSM	0.897
HLGN	0.892
BAK	0.89
HKIB	0.888
STZ	0.888
SDCI	0.886
WE	0.884

10 Most Negative Correlations
IRL	-0.903
PANA	-0.883
IVH	-0.878
GOGN	-0.878
GOTU	-0.872
MGU	-0.871
ESM-UN	-0.871
STAR-PI	-0.869
HWKZ	-0.868
SGU	-0.866

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Bristol-Myers Squibb Co Correlation - Currency/Commodity

-0.50
( weak negative )

-0.54
( weak negative )

0.00
( neutral )

-0.52
( weak negative )

-0.11
( neutral )

0.70
( moderate )

Bristol-Myers Squibb Co Financials

Annual	2023
Revenue:	$45.01B
Gross Profit:	$34.31B (76.24 %)
EPS:	$3.88

Q4	2023
Revenue:	$11.48B
Gross Profit:	$8.73B (76.08 %)
EPS:	$0.870

Q3	2023
Revenue:	$10.97B
Gross Profit:	$8.46B (77.15 %)
EPS:	$0.940

Q2	2023
Revenue:	$11.23B
Gross Profit:	$8.35B (74.38 %)
EPS:	$0.990

Financial Reports:

No articles found.

Bristol-Myers Squibb Co Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0.540 (N/A)	$0.570 (N/A)	$0.570 (N/A)	$0.570 (N/A)	$0.570 (N/A)	$0.600 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Bristol-Myers Squibb Co Dividend Information - Dividend King

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.51 - Stable (10.20%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.00892	1972-07-26
Last Dividend	$0.600	2024-01-04
Next Dividend	$0	N/A
Payout Date	2024-02-01
Next Payout Date	N/A
# dividends	206	--
Total Paid Out	$44.07	--
Avg. Dividend % Per Year	2.48%	--
Score	5.88	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.51
Div. Directional Score	7.97	--

Next Divdend (Est)
(2024-08-12)

$0.605 Estimate 60.24 %

Dividend Stability

0.96 Excellent

Dividend Score

5.88

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
1972	$0.0178	0.95%
1973	$0.0482	2.36%
1974	$0.0452	3.25%
1975	$0.0491	3.23%
1976	$0.0536	2.60%
1977	$0.0655	3.24%
1978	$0.0725	3.64%
1979	$0.0856	4.04%
1980	$0.0714	3.31%
1981	$0.106	3.50%
1982	$0.121	3.85%
1983	$0.174	4.36%
1984	$0.190	3.71%
1985	$0.224	3.67%
1986	$0.214	2.74%
1987	$0.250	2.49%
1988	$0.519	5.04%
1989	$0.483	4.57%
1990	$0.521	3.84%
1991	$0.593	3.74%
1992	$0.492	2.34%
1993	$0.685	4.34%
1994	$0.871	6.37%
1995	$0.528	3.80%
1996	$0.893	4.38%
1997	$0.728	2.86%
1998	$0.557	1.24%
1999	$0.820	1.32%
2000	$0.932	1.52%
2001	$1.061	1.56%
2002	$1.400	2.75%
2003	$1.120	4.66%
2004	$0.840	2.86%
2005	$1.120	4.40%
2006	$1.120	4.82%
2007	$1.120	4.25%
2008	$1.550	5.93%
2009	$1.250	5.23%
2010	$0.960	3.75%
2011	$1.320	4.97%
2012	$1.360	3.88%
2013	$1.760	5.38%
2014	$1.450	2.77%
2015	$1.490	2.50%
2016	$1.140	1.70%
2017	$1.560	2.62%
2018	$1.600	2.61%
2019	$1.640	3.13%
2020	$2.29	3.62%
2021	$1.470	2.39%
2022	$2.16	3.49%
2023	$2.28	3.16%
2024	$0.600	1.14%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50
MTR	Dividend Diamond	2023-10-30	Monthly	39	10.10%	8.50
PDI	Dividend Royal	2023-11-10	Monthly	13	7.86%	8.50
GOF	Dividend Royal	2023-11-14	Monthly	18	8.03%	8.50
ZTR	Dividend King	2024-02-09	Monthly	37	8.35%	8.50
ORC	Dividend Royal	2023-11-29	Monthly	12	9.23%	8.50
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
NCZ	Dividend Royal	2024-02-09	Monthly	22	7.79%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.178	1.500	6.43	9.65	[0 - 0.5]
returnOnAssetsTTM	0.0843	1.200	7.19	8.63	[0 - 0.3]
returnOnEquityTTM	0.263	1.500	8.19	10.00	[0.1 - 1]
payoutRatioTTM	0.591	-1.000	4.09	-4.09	[0 - 1]
currentRatioTTM	1.427	0.800	7.86	6.29	[1 - 3]
quickRatioTTM	1.237	0.800	7.43	5.94	[0.8 - 2.5]
cashRatioTTM	0.515	1.500	8.25	10.00	[0.2 - 2]
debtRatioTTM	0.436	-1.500	2.74	-4.11	[0 - 0.6]
interestCoverageTTM	11.06	1.000	7.01	7.01	[3 - 30]
operatingCashFlowPerShareTTM	6.84	2.00	7.72	10.00	[0 - 30]
freeCashFlowPerShareTTM	6.24	2.00	6.88	10.00	[0 - 20]
debtEquityRatioTTM	1.409	-1.500	4.36	-6.55	[0 - 2.5]
grossProfitMarginTTM	0.762	1.000	0.627	0.627	[0.2 - 0.8]
operatingProfitMarginTTM	0.287	1.000	6.27	6.27	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.334	1.000	9.25	9.25	[0.2 - 2]
assetTurnoverTTM	0.473	0.800	-0.180	-0.144	[0.5 - 2]
Total Score				10.43

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	12.34	1.000	8.85	0	[1 - 100]
returnOnEquityTTM	0.263	2.50	8.84	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	6.24	2.00	7.92	10.00	[0 - 30]
dividendYielPercentageTTM	4.79	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.84	2.00	7.72	10.00	[0 - 30]
payoutRatioTTM	0.591	1.500	4.09	-4.09	[0 - 1]
pegRatioTTM	0.0311	1.500	-3.13	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.308	1.000	4.80	0	[0.1 - 0.5]
Total Score				5.51

Bristol-Myers Squibb Co

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Realtime updates for Bristol-Myers Squibb Co [BMY]

Upcoming Earnings Alert

Bristol-Myers Squibb Co Dividend Information - Dividend King

Dividend Commentary

Top 10 dividend Companies for NYSE

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)